Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer (Q43685297)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 December 2012

Language	Label	Description	Also known as
English	Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer	scientific article published on 21 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

11

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Angeles Alvarez Secord

10

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

9

object named as

Paola A Gehrig

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3

object named as

Robin A Laskey

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Marek S Poniewierski

2

object named as

Marek S Poniewierski

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

4

object named as

Micael A Lopez

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1

object named as

Rabbie K Hanna

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

12

object named as

Gary H Lyman

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Aaron Shafer

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Linda Van Le

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jeffrey Crawford

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

David C Dale

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

21 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

74-80

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

The impact of received dose intensity on the outcome of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Impact of chemotherapy dose intensity on cancer patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.017

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.12.017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43685297&oldid=2102495742"